Pay in 4 interest-free payments of $7.36 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
How Many Americans Use GLP-1 Medications
Transcriptomic patient dataset analysis revealed marked alterations in P 2 Y 12 expression in microglia from individuals with Multiple Sclerosis
Retatrutide vs Tirzepatide vs Semaglutide Three compounds dominate current GLP-1-class research conversation: semaglutide (single agonist), tirzepatide (dual agonist), and retatrutide (triple agonist) [3][4][9]
[49]Yu G, Chen Q, et al
Once approved, here is what the pricing landscape looks like based on comparable drugs: Semaglutide (Wegovy) without insurance runs $1,300 to $1,600 per month in the US Tirzepatide (Zepbound) without insurance runs $1,000 to $1,300 per month in the US Retatrutide, as a next-generation triple agonist, will likely land at $1,200 to $1,800 per month at launch In Australia, the UK, and Canada, prices tend to be lower due to government drug pricing controls
US$ 24.86
US$ 28.87
US$ 26.75
